Peter DeMuth
Technik-/Wissenschafts-/F&E-Leiter bei ELICIO THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Peter DeMuth is currently the Chief Scientific Officer at Elicio Therapeutics, Inc. He started this position in 2022.
He holds a doctorate degree from the Massachusetts Institute of Technology, which he received in 2013.
He also has an undergraduate degree from the University of Maryland, which he obtained in 2008.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 10.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Peter DeMuth
| Unternehmen | Position | Beginn |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2022 |
Ehemalige bekannte Positionen von Peter DeMuth
| Unternehmen | Position | Ende |
|---|---|---|
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2023 |
Ausbildung von Peter DeMuth
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ELICIO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
